Tepotinib - Merck KGaA

Drug Profile

Tepotinib - Merck KGaA

Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono; Merck KGaA; Merck Serono
  • Class Antineoplastics; Nitriles; Piperidines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Apr 2018 Merck plans a phase I trial (Combination therapy, Monotherapy, In volunteers) in Germany (PO) in May 2018 (NCT03492437) (EudraCT2017-004074-34)
  • 29 Mar 2018 Phase I development for Solid tumours (Second-line therapy or greater) is ongoing in USA and Japan (PO, Capsule) (NCT01014936)
  • 27 Mar 2018 Tepotinib receives SAKIGAKE 'fast-track' designation for Non-small cell lung cancer (harboring MET exon 14 skipping mutations) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top